Termination of Participation in Collaborative Development. On a Collaboration Lead Compound-by-Collaboration Lead Compound basis, either Party may elect (upon [ * ] written notice following receipt by the Party contemplating termination of its participation in the Pre-Clinical Development of any Collaboration Lead Compound or Development of any Product of Development Termination Documents) to terminate its participation in, or to not to participate in, the Pre-Clinical Development of any Collaboration Lead Compound or Development of any Product. "Development Termination [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Appears in 4 contracts
Samples: Preliminary Research, Development and Marketing Agreement (Tularik Inc), Preliminary Research, Development and Marketing Agreement (Tularik Inc), Preliminary Research, Development and Marketing Agreement (Tularik Inc)
